NCT05815498: A reported trial by ModernaTX, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05815498 |
|---|---|
| Title | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283 Compared With mRNA-1273 in Participants Aged ≥12 Years for the Prevention of COVID-19 |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 28, 2023 |
| Completion date | April 12, 2025 |
| Required reporting date | April 12, 2026, midnight |
| Actual reporting date | April 10, 2026 |
| Date last checked at ClinicalTrials.gov | May 22, 2026 |
| Days late | None |